My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Natera, Inc. - Common Stock (NQ:NTRA)

231.25 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Natera, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

3 Reasons Why This Natera Analyst Says The Selloff Is Overdone ↗

March 09, 2022

Natera Inc (NASDAQ: NTRA) analyst Kyle Mikson of Canaccord Genuity Capital reiterated a Buy rating Wednesday on the genetic testing company...

Via Benzinga

USO, XOM, MRO, DVN: Why Are Oil Stocks Down Today? ↗

March 09, 2022

Oil stocks are on their way down today and we're diving into what has these shares slipping in a market update for Wednesday!

Via InvestorPlace

Why Is Natera (NTRA) Stock Down Today? ↗

March 09, 2022

NTRA stock has lost more than 35% following a short report by Hindenburg Research. The report alleges fraud, among other claims.

Via InvestorPlace

Mid-Day Market Update: Nasdaq Surges 375 Points; Bumble Shares Spike Higher ↗

March 09, 2022

U.S. stocks traded higher midway through trading, with the Nasdaq surging 375 points on Wednesday. The Dow traded up 2% to 33,284.15 while the NASDAQ rose 2.93% to 13,170.68. The...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

March 09, 2022

During Wednesday's session, 35 companies made new 52-week lows. 52-Week High And Low Highlights: The company with the largest market cap to set a new 52-week low was...

Via Benzinga

Analyst Ratings For Natera ↗

March 08, 2022

Over the past 3 months, 4 analysts have published their opinion on Natera (NASDAQ:NTRA) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

50 Stocks Moving In Wednesday's Mid-Day Session ↗

March 09, 2022

Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) rose 148% to $3.78. Sunshine Biopharma, last month, priced its 1.88 million unit uplisting to Nasdaq at $4.25 per unit. Direct...

Via Benzinga

Mid-Morning Market Update: Markets Open Higher; Dow Jumps Over 600 Points ↗

March 09, 2022

U.S. stocks traded opened on a strong note this morning, with the Dow Jones jumping more than 600 points on Wednesday. Following the market opening Wednesday, the Dow traded up 1....

Via Benzinga

Natera: Q4 Earnings Insights ↗

February 24, 2022

Natera (NASDAQ:NTRA) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Natera...

Via Benzinga

Natera's Debt Overview ↗

February 22, 2022

Over the past three months, shares of Natera (NASDAQ:NTRA) decreased by 34.50%. Before we understand the importance of debt, let us look at how much debt Natera has. Check...

Via Benzinga

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO ↗

August 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

Analyzing Natera's Unusual Options Activity ↗

August 04, 2021

On Wednesday, shares of Natera (NASDAQ:NTRA) saw unusual o...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022 ↗

March 08, 2022

Upgrades According to Janney Montgomery Scott, the prior rating for Wintrust Financial Corp (NASDAQ:WTFC) was changed from Neutral to Buy. Wintrust Finl earned $1.58 in the fourth...

Via Benzinga

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗

February 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

FeganScott Announces Investigation into Prenatal Testing Options Revealing Flawed Genetic Results

January 17, 2022

--News Direct--

Via News Direct

What Does Natera's Debt Look Like? ↗

August 03, 2021

Over the past three months, shares of Natera (NASDAQ:NTRA) moved higher by 10.31%. Before we understand the importance of debt, let us look at how much debt Natera has....

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

January 07, 2022

Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana (NYSE:HUM) was the biggest company on a market cap...

Via Benzinga

7 Stocks to Buy in November in Light of Their October Dip ↗

November 15, 2021

October was a good month in the markets. It won't be easy to find stocks to buy on the dip. However, here are seven that will do the trick.

Via InvestorPlace

Medicare Coverage For Natera's Signatera For Pan-Cancer Immunotherapy Monitoring ↗

November 11, 2021

CMS Molecular Diagnostics Services Program (MolDX) has issued a final local coverage determination (LCD) for pan-cancer immunotherapy monitoring using Natera Inc...

Via Benzinga

Natera Raises FY21 Sales Outlook After Mixed Q3 earnings ↗

November 05, 2021

Natera Inc (NASDAQ: NTRA) posted Q3 sales of $158.1 million, +61% Y/Y, beating the consensus of $151.36 million, driven by an increase in test volume and product...

Via Benzinga

Natera Inc (NTRA) Q3 2021 Earnings Call Transcript ↗

November 05, 2021

NTRA earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

CEO And President Of Natera Trades $2.4M In Company Stock ↗

October 06, 2021

Leonard Steven Chapman, CEO And President at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on October 5, according to a new SEC filing. What Happened: A Form 4...

Via Benzinga

Topics Regulatory Compliance

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗

November 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...

Via Benzinga

Notable Natera Insider Trades $3M In Company Stock ↗

September 30, 2021

Burkes Michael Brophy, Chief Financial Officer at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on September 28, according to a new SEC filing. What Happened:...

Via Benzinga

Topics Regulatory Compliance

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

CEO And President Of Natera Trades $3.41 Million In Company Stock ↗

September 27, 2021

Leonard Steven Chapman, CEO And President at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on September 24, according to a new SEC filing. What Happened: A...

Via Benzinga

Topics Regulatory Compliance

Return on Capital Employed Overview: Natera ↗

August 30, 2021

After pulling data from Benzinga Pro it seems like during Q2, Natera (NASDAQ:NTRA) brought in sales totaling $142.03 million. However, earnings decreased 82.96%, resulting in a...

Via Benzinga

Natera Q2 Sales Tops Street Estimates On Higher Volumes, Raises FY21 Sales Outlook ↗

August 06, 2021

Natera Inc's (NASDAQ: NTRA) second-quarter revenues jumped 64% Y/Y $142 million, driven by an increase in test volume and product revenues, sharply ahead of the consensus...

Via Benzinga

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗

August 01, 2021

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.